Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

HER2 mutation status in Japanese HER2-negative breast cancer patients.

Endo Y, Dong Y, Yoshimoto N, Asano T, Hato Y, Yamashita H, Sato S, Takahashi S, Fujii Y, Toyama T.

Jpn J Clin Oncol. 2014 Jul;44(7):619-23. doi: 10.1093/jjco/hyu053. Epub 2014 May 5.

2.

Expression profiling of breast tumors based on human epidermal growth factor receptor 2 status defines migration-related genes.

Cuadros M, Cano C, López FJ, López-Castro R, Concha A.

Pathobiology. 2013;80(1):32-40. doi: 10.1159/000339431. Epub 2012 Jul 24.

PMID:
22832278
3.

Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer.

Shah SS, Ketterling RP, Goetz MP, Ingle JN, Reynolds CA, Perez EA, Chen B.

Hum Pathol. 2010 Jan;41(1):103-6. doi: 10.1016/j.humpath.2009.07.001. Epub 2009 Sep 16.

PMID:
19762065
4.

Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer.

Grob TJ, Heilenkötter U, Geist S, Paluchowski P, Wilke C, Jaenicke F, Quaas A, Wilczak W, Choschzick M, Sauter G, Lebeau A.

Breast Cancer Res Treat. 2012 Jul;134(2):561-7. doi: 10.1007/s10549-012-2092-7. Epub 2012 May 19.

PMID:
22610646
5.

Deletion of the inhibitor of growth 4 (ING4) tumor suppressor gene is prevalent in human epidermal growth factor 2 (HER2)-positive breast cancer.

Tapia C, Zlobec I, Schneider S, Kilic E, Güth U, Bubendorf L, Kim S.

Hum Pathol. 2011 Jul;42(7):983-90. doi: 10.1016/j.humpath.2010.10.012. Epub 2011 Feb 11.

6.

Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy.

Tse CH, Hwang HC, Goldstein LC, Kandalaft PL, Wiley JC, Kussick SJ, Gown AM.

J Clin Oncol. 2011 Nov 1;29(31):4168-74. doi: 10.1200/JCO.2011.36.0107. Epub 2011 Sep 26.

7.

HER2 mutation status in Japanese HER2-positive breast cancer patients.

Endo Y, Dong Y, Kondo N, Yoshimoto N, Asano T, Hato Y, Nishimoto M, Kato H, Takahashi S, Nakanishi R, Toyama T.

Breast Cancer. 2015 Dec 7. [Epub ahead of print]

PMID:
26642960
8.

A comparison of HER2/neu gene amplification and its protein overexpression between primary breast cancer and metastatic lymph nodes.

Aoyama K, Kamio T, Nishikawa T, Kameoka S.

Jpn J Clin Oncol. 2010 Jul;40(7):613-9. doi: 10.1093/jjco/hyq019. Epub 2010 Mar 4.

10.

Activating HER2 mutations in HER2 gene amplification negative breast cancer.

Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, Monsey J, Goel N, Aronson AB, Li S, Ma CX, Ding L, Mardis ER, Ellis MJ.

Cancer Discov. 2013 Feb;3(2):224-37. doi: 10.1158/2159-8290.CD-12-0349. Epub 2012 Dec 7.

12.

Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers.

Lamy PJ, Fina F, Bascoul-Mollevi C, Laberenne AC, Martin PM, Ouafik L, Jacot W.

Breast Cancer Res. 2011 Feb 2;13(1):R15. doi: 10.1186/bcr2824.

13.

CK19, CK20, EGFR and HER2 status of circulating tumor cells in patients with breast cancer.

Tunca B, Egeli U, Cecener G, Tezcan G, Gökgöz S, Tasdelen I, Bayram N, Tolunay S, Umut G, Demirdogen E, Erturk E, Ak S, Cetintas S, Evrensel T.

Tumori. 2012 Mar-Apr;98(2):243-51. doi: 10.1700/1088.11937.

PMID:
22677992
14.

Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial.

Bartlett JM, Munro A, Cameron DA, Thomas J, Prescott R, Twelves CJ.

J Clin Oncol. 2008 Nov 1;26(31):5027-35. doi: 10.1200/JCO.2007.14.6597. Epub 2008 Sep 2.

15.

Validation of a new classifier for the automated analysis of the human epidermal growth factor receptor 2 (HER2) gene amplification in breast cancer specimens.

Furrer D, Jacob S, Caron C, Sanschagrin F, Provencher L, Diorio C.

Diagn Pathol. 2013 Feb 4;8:17. doi: 10.1186/1746-1596-8-17.

17.

HER2 in breast cancer: a review and update.

Krishnamurti U, Silverman JF.

Adv Anat Pathol. 2014 Mar;21(2):100-7. doi: 10.1097/PAP.0000000000000015. Review.

PMID:
24508693
18.

The hormone receptor, human epidermal growth factor receptor 2, and molecular subtype status of individual tumor foci in multifocal/multicentric invasive ductal carcinoma of breast.

Choi Y, Kim EJ, Seol H, Lee HE, Jang MJ, Kim SM, Kim JH, Kim SW, Choe G, Park SY.

Hum Pathol. 2012 Jan;43(1):48-55. doi: 10.1016/j.humpath.2010.08.026. Epub 2011 Jul 5.

PMID:
21733550
19.

Serum HER2 levels and HER2 status in tumor cells in advanced gastric cancer patients.

Sasaki T, Fuse N, Kuwata T, Nomura S, Kaneko K, Doi T, Yoshino T, Asano H, Ochiai A, Komatsu Y, Sakamoto N, Ohtsu A.

Jpn J Clin Oncol. 2015 Jan;45(1):43-8. doi: 10.1093/jjco/hyu174. Epub 2014 Nov 6.

20.
Items per page

Supplemental Content

Write to the Help Desk